Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Primary objective: To determine the levels of malondialdehyde (MDA) and immunohistochemistry
surrogate of inflammation in patients with NSAID-induced gastric mucosal injury treated with
Rebamipide 3x a day vs Esomeprazole 40mg once a day. Secondary objective: For patients who
become symptomatic during NSAID treatment, to compare the proportion of patients with
positive treatment effects using the Likert scale. Third objective: To compare the proportion
of patients with positive treatment effects as determined by Modified Lanza scoring between
the two groups.